Mr. Richman continued, "Medison Pharma is a leading marketer of numerous high profile pharmaceutical products for companies such as Biogen Idec, Shire, Ipsen and Boston Scientific and has built an outstanding reputation throughout Israel. The strength of their organization, coupled with their expertise in commercialization and distribution, will be invaluable as we continue to expand the market opportunity for our biodefense products internationally."
Rachel Kipnis, Marketing Manager of Medison Pharma, commented, "PharmAthene's biodefense products represent important new advancements in the prevention and treatment of high-risk biological and chemical threats to Israel. Medison regards this partnership as critical, considering Israel's location and the global threats it faces. Accordingly, we are delighted to align ourselves with PharmAthene, a leading company in the biodefense sector, and look forward to bringing their products to market in Israel."
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposu
|SOURCE PharmAthene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved